Browsing by Author George, Joshy

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 14 of 14
Issue DateTitleAuthor(s)Citation
2014ABCA transporter gene expression and poor outcome in epithelial ovarian cancerdeFazio, Anna; Emmanuel, Catherine; Gao, Bo; Harnett, Paul; Beesley, Johnathan; Chen, Xiaoqing; et al, Various; Flemming, Claudia L.; George, Joshy; Hedditch, Ellen; Johnatty, Sharon E.; Li, Yi; Russell, Amanda; Study Group, Australian Ovarian Cancer; William, Rebekka T; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Obstetrics & Gynaecology; Western Clinical School: Medicine (Westmead)ABCA transporter gene expression and poor outcome in epithelial ovarian cancer, Journal of the National Cancer Institute, vol.106, 7, 2014,pp 1-11
2012BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupdeFazio, Anna; Emmanuel, Catherine; Alsop, Kathryn; Birrer, Michael; Bowtell, David D L; Dobrovic, Alexander; Fereday, Sian; Fox, Stephen B.; Friedlander, Michael; George, Joshy; Meldrum, Cliff; Mitchell, Gillian; Stewart, Colin; Webb, Penelope M.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteBRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group, Journal of Clinical Oncology, vol.30, 21, 2012,pp 2654-2663
2011Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian CancersdeFazio, Anna; Anglesio, Michael S.; Cowin, Prue; et al, various; Etemadmoghadam, Dariush; George, Joshy; Helland, Aslaug; House, Colin; Johnstone, Cameron; Melnyk, Nataliya; Rustgi, Anil K.; Sheppard, Karen; Western Clinical School: Westmead Millennium InstituteDeregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers, PLoS One, vol.6, 4, 2011,pp Article number e18064-1-Article number e18064-9
2014Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driverBalleine, Rosemary; Brand, Alison; Clarke, Christine; deFazio, Anna; Emmanuel, Catherine; Harnett, Paul; Hogg, Russell; Kennedy, Catherine Jane; Sharma, Raghwa; Wain, Gerard; Anglesio, Michael S.; Chiew, Yoke-Eng; et al, Various; Etemadmoghadam, Dariush; Fereday, Sian; Galletta, Laura; George, Joshy; Hung, Jillian A.; MacConaill, Laura; Palescandolo, Emanuele; Russell, P; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Medicine (Westmead); Western Clinical School: Pathology; Western Clinical School: Obstetrics & GynaecologyGenomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver, Clinical Cancer Research, vol.20, 24, 2014,pp 6618-6630
2015The genomic landscape of phaeochromocytomaBenn, Diana; Clifton-Bligh, Roderick; Gill, Anthony; Robinson, Bruce; Flynn, Aidan; Fox, Stephen B.; George, Joshy; Hicks, Rodney J.; Hogg, Annette; James, Paul; Li, Jason; McArthur, Grant A.; Tothill, Richard W.; Trainer, Alison; Waldeck, Kelly; Northern Clinical School: Kolling Institute; Northern Clinical School: Medicine; Northern Clinical School: Pathology; Northern Clinical School: MedicineThe genomic landscape of phaeochromocytoma, Journal of Pathology, vol.236, 1, 2015,pp 78-89
2011IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell CancerdeFazio, Anna; Anglesio, Michael S.; Australian Ovarian Cancer Study Group, (AOCSG); Balkwill, Frances; Birrer, Michael J.; Bowtell, David D L; Campbell, Ian G.; Chakravarty, Probir; Coward, Jermaine; Cowin, Prue; Friedlander, Michael L.; George, Joshy; Gilks, B; Gorringe, Kylie; House, Colin; Huntsman, David; Kalloger, Steve; Kulbe, Hagen; Lemech, Charlotte; Okamoto, Aikou; Power, Jeremy; Rischin, D.; Western Clinical School: Westmead Millennium InstituteIL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer, Clinical Cancer Research, vol.17, 8, 2011,pp 2538-2548
2009Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies DistinctMechanisms of Primary Chemoresistance in Ovarian CarcinomasChiew, Y; Defazio, Anna; Harnett, Paul; Beroukhim, Rameen; et al, Not Known; Etemadmoghadam, Dariush; George, Joshy; Getz, Gad; Late, Stephen; Mermel, Craig; Okamoto, Aikou; Raeder, Maria B.; Tothill, Richard W.; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies DistinctMechanisms of Primary Chemoresistance in Ovarian Carcinomas, Clinical Cancer Research, vol.15,(4),2009,pp 1417-1427
2012LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal DoxorubicindeFazio, Anna; Harnett, Paul; Anglesio, Michael; Cowin, Prue; Cullinane, Carleen; et al, Various; Etemadmoghadam, Dariush; Fereday, Sian; Ftouni, Sarah; Galletta, Laura; George, Joshy; Loehrer, Elizabeth; Van Loo, Peter; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin, Cancer Research, vol.72, 16, 2012,pp 4060-4073
2008Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.deFazio, Anna; Russell, Peter; Anglesio, Michael S.; Arnold, Jeremy; Australian Ovarian Cancer Study Group, (AOCSG); Birrer, Michael J.; Bowtell, David D L; Chenevix-Trench, Georgia; Fereday, Sian; George, Joshy; Locandro, Bianca; Sharma, Raghwa; Simms, Lisa; Tinker, A. V.; Tothill, Richard W.; Traficante, Nadia; Waddell, Nic; Western Clinical School: Westmead Millennium Institute; Central Clinical School: PathologyMutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors., Molecular Cancer Research, vol.6, 11, 2008,pp 1678-1690
2017A Myc activity signature predicts poor clinical outcomes in Myc-associated cancersdeFazio, Anna; Bowtell, David D L; et al, Various; George, Joshy; Jung, MoonSun; Liu, Bing; Liu, Pei Yan; Liu, Tao; London, Wendy; Oberthuer, Andre; Russell, Amanda; Western Clinical School: Westmead Institute for Medical ResA Myc activity signature predicts poor clinical outcomes in Myc-associated cancers, Cancer Research, vol.77, 4, 2017,pp 971-981
2013Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutationsdeFazio, Anna; Alsop, Kathryn; Bowtell, David D L; Dobrovic, Alexander; Etemadmoghadam, Dariush; George, Joshy; Hondow, Heather; Levine, Douglas; Mikeska, Thomas; Mitchell, Gillian; Smyth, Gordon; Western Clinical School: Westmead Millennium InstituteNonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations, Clinical Cancer Research, vol.19, 13, 2013,pp 3474-3484
2008Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.deFazio, Anna; Australian Ovarian Cancer Study Group, (AOCSG); Bowtell, David D L; Brown, Robert; Chiew, Yoke-Eng; Etemadmoghadam, Dariush; Fereday, Sian; Fox, Stephen B.; George, Joshy; Gertig, Dorota; Haviv, Izhak; Hung, Jillian A.; Johnson,, Daryl S.; Lade, Stephen; Locandro, Bianca; Tinker, Anna V.; Tothill, Richard W.; Traficante, Nadia; Trivett, Melanie K.; Western Clinical School: Westmead Millennium InstituteNovel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome., Clinical Cancer Research, vol.14, 16, 2008,pp 5198-5208
2014RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomasMcKay, Michael; Deb, Siddhartha; Fox, Stephen B.; George, Joshy; Hawkins, Nicholas; Li, J; Mortensen, Neil James; Ramsay, Robert G.; Tuynman, Jurriaan; Ward, Robyn; Xu, Huiling; Yan, Yuqian; MedicineRAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas, British Journal of Cancer, vol.110, 6, 2014,pp 1606-1613
2015Whole-genome characterization of chemoresistant ovarian cancerChiew, Yoke-Eng; deFazio, Anna; Harnett, Paul; Hung, Jillian; Kennedy, Catherine Jane; McNally, Orla; Alsop, Kathryn; Bailey, Peter; Christie, Elizabeth; Cowin, Prue; et al, Various; Etemadmoghadam, Dariush; Fereday, Sian; Garsed, Dale; George, Joshy; Nones, Katia; Patch, Anne-Marie; Western Clinical School: Obstetrics & Gynaecology; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead); Western Clinical School: Obstetrics & Gynaecology; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Millennium InstituteWhole-genome characterization of chemoresistant ovarian cancer, Nature, vol.521, 7553, 2015,pp 489-494